| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3468 | 2016 |
| A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma W Yeo, TS Mok, B Zee, TWT Leung, PBS Lai, WY Lau, J Koh, FKF Mo, ... Journal of the National Cancer Institute 97 (20), 1532-1538, 2005 | 801 | 2005 |
| Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised … J Li, S Qin, R Xu, TCC Yau, B Ma, H Pan, J Xu, Y Bai, Y Chi, L Wang, ... The lancet oncology 16 (6), 619-629, 2015 | 797 | 2015 |
| Overall survival after concurrent cisplatin–radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma ATC Chan, SF Leung, RKC Ngan, PML Teo, WH Lau, WH Kwan, EP Hui, ... Journal of the National Cancer Institute 97 (7), 536-539, 2005 | 718 | 2005 |
| Management of nasopharyngeal carcinoma: current practice and future perspective AWM Lee, BBY Ma, WT Ng, ATC Chan Journal of clinical oncology 33 (29), 3356-3364, 2015 | 715 | 2015 |
| Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma EP Hui, BB Ma, SF Leung, AD King, F Mo, MK Kam, BK Yu, SK Chiu, ... Journal of clinical oncology 27 (2), 242-249, 2009 | 676 | 2009 |
| Analysis of plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer KCA Chan, JKS Woo, A King, BCY Zee, WKJ Lam, SL Chan, SWI Chu, ... New England Journal of Medicine 377 (6), 513-522, 2017 | 656 | 2017 |
| Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma ATC Chan, YMD Lo, B Zee, LYS Chan, BBY Ma, SF Leung, F Mo, M Lai, ... Journal of the National Cancer Institute 94 (21), 1614-1619, 2002 | 481 | 2002 |
| Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing KCA Chan, P Jiang, CWM Chan, K Sun, J Wong, EP Hui, SL Chan, ... Proceedings of the National Academy of Sciences 110 (47), 18761-18768, 2013 | 474 | 2013 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 456 | 2019 |
| Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma ATC Chan, MM Hsu, BC Goh, EP Hui, TW Liu, MJ Millward, RL Hong, ... Journal of clinical oncology 23 (15), 3568-3576, 2005 | 413 | 2005 |
| Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742) BBY Ma, WT Lim, BC Goh, EP Hui, KW Lo, A Pettinger, NR Foster, ... Journal of Clinical Oncology 36 (14), 1412, 2018 | 401 | 2018 |
| Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma S Leung, B Zee, BB Ma, EP Hui, F Mo, M Lai, KCA Chan, LYS Chan, ... Journal of clinical oncology 24 (34), 5414-5418, 2006 | 390 | 2006 |
| Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations YY Li, GTY Chung, VWY Lui, KF To, BBY Ma, C Chow, JKS Woo, KY Yip, ... Nature communications 8 (1), 14121, 2017 | 299 | 2017 |
| New utility of an old marker: serial α-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic … SL Chan, FKF Mo, PJ Johnson, EP Hui, BBY Ma, WM Ho, KC Lam, ... Journal of Clinical Oncology 27 (3), 446-452, 2009 | 288 | 2009 |
| Nasopharyngeal carcinoma: an evolving paradigm KCW Wong, EP Hui, KW Lo, WKJ Lam, D Johnson, L Li, Q Tao, ... Nature reviews Clinical oncology 18 (11), 679-695, 2021 | 276 | 2021 |
| Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy W Yeo, KC Lam, B Zee, PSK Chan, FKF Mo, WM Ho, WL Wong, ... Annals of oncology 15 (11), 1661-1666, 2004 | 243 | 2004 |
| Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline YP Chen, N Ismaila, MLK Chua, AD Colevas, R Haddad, SH Huang, ... Journal of Clinical Oncology 39 (7), 840-859, 2021 | 231 | 2021 |
| Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal … BBY Ma, TCW Poon, KF To, B Zee, FKF Mo, CML Chan, S Ho, PML Teo, ... Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2003 | 227 | 2003 |
| Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma BBY Ma, ATC Chan Cancer 103 (1), 22-31, 2005 | 222 | 2005 |
Anthony T.C. ChanLi Shu Fan Medical Foundation Professor of Clinical Oncology,The Chinese University of Hong Kong在 clo.cuhk.edu.hk 的电子邮件经过验证
